Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
4,769 people get GALE articles and Market Currents by email alert.
Get email alerts on GALE »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 9, 2013)
-
-
GlobeNewswire (May 1, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
-
GlobeNewswire (Apr 16, 2013)
-
-
-
-
GlobeNewswire (Mar 29, 2013)
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
There are no Transcripts on GALE.
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 1, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 16, 2013)
-
GlobeNewswire (Mar 29, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Mar 4, 2013)
-
GlobeNewswire (Feb 5, 2013)
-
GlobeNewswire (Dec 18, 2012)
-
GlobeNewswire (Dec 17, 2012)
-
GlobeNewswire (Dec 5, 2012)
-
GlobeNewswire (Dec 4, 2012)
-
GlobeNewswire (Nov 20, 2012)
GALE vs. ETF Alternatives
Company Description
Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com. More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 5:39 PM Galena Biopharma (GALE): Q1 EPS of -$0.11 misses by $0.04. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, November 13, 2012, 10:59 AM Shares of Galena Biopharma (GALE +12.9%) are on a tear this morning after reporting a better than anticipated Q3 loss of $0.09 per share, narrower than the prior year's EPS loss of $0.13 and beating the Street consensus for a loss of $0.10. Operating losses decreased Y/Y, largely due to writedown's taken during Q311 due to discontinued operations, which were driven by the company's ongoing, late-stage trial for NeuVax and the spin-off of a pharmaceuticals subsidiary. Comment! [Healthcare, Earnings, On the Move]
-
- View all 2 replies
-
JMattius: Ran too far too fast is my guess. See CPRX get shorted like crazy after it doubled in three days. -
-
- View all 0 replies
-
- View all 1 replies
-
Owen Bernard: Not sure you found any answers - most interesting was a new B.O.D. joined $GALE, William L. Ashton. Definitely an attention getter.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
Robert Schwartz
Galena Biopharma ($GALE): What to know before you invest http://seekingalpha.com/p/z54r - View all 3 replies
-
Robert Schwartz: They are missing quite a bit. Take a look at their characterization of the Phase-I/II-data, it is way off base.
-
isafin: So, the recent wobble of the stock price can be substantiated by other than speculative trends reasons. Thank you.
LATEST REPLIES
-
- View all 2 replies
-
JMattius: Ran too far too fast is my guess. See CPRX get shorted like crazy after it doubled in three days.
-
-
- View all 1 replies
-
Owen Bernard: Not sure you found any answers - most interesting was a new B.O.D. joined $GALE, William L. Ashton. Definitely an attention getter.
-
- View all 2 replies
-
-
-
Robert Schwartz
Galena Biopharma ($GALE): What to know before you invest http://seekingalpha.com/p/z54r - View all 3 replies
-
Robert Schwartz: They are missing quite a bit. Take a look at their characterization of the Phase-I/II-data, it is way off base.
-
isafin: So, the recent wobble of the stock price can be substantiated by other than speculative trends reasons. Thank you.
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
Rich Steffens
If I had free $, I'd start my position in $GALE, especially after learning from COL GEP of AF's inaccuracies. - View all 12 replies
-
Ron Reed: week later when it falls back down. Great idea company just no sense in how to turn it into money for the investor.
-
Rich Steffens: 11/27 AF made false claims. GALE closed @ 1.58. A trade long was born. 11/29 @ 2.04. 12/04 @ 2.24. Take profit, when so high, add later.
-
- View all 1 replies
-
smokeyRose: Because it's A Bio-Pharm. They Have No Stability at all.........Unless of course someBody on the inside Knows about Drug approval and or Dis
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 2 replies
-
EvrClrx311: I'm sure in another year I'll be saying "wish I had owned more than just 5000 shares when GALE was at $2"
-
NYorkerinUT: You just never know sometimes. I was considering GALE when it was under a buck, but thought it might get de-listed or reverse split.
-
- View all 5 replies
-
-
-
- View all 4 replies
-
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
